サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1720813

家族性異型高コレステロール血症管理の世界市場レポート 2025年

Heterozygous Familial Hypercholesterolemia Management Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
家族性異型高コレステロール血症管理の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

家族性異型高コレステロール血症管理の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.1％で183億7,000万米ドルに成長します。予測期間中の成長は、遠隔医療サービスの拡大、慢性疾患の有病率の上昇、臨床試験数の増加、老人人口の増加、医薬品パイプライン開発の急増に起因すると考えられます。予測期間における主な動向としては、デジタルヘルスソリューションの統合、治療オプションの進歩、併用療法の開発、技術革新、新規治療の出現などが挙げられます。

心血管疾患の有病率の増加は、家族性異型高コレステロール血症管理市場の拡大を促進すると予想されます。心血管疾患（CVD）には、冠動脈疾患、心不全、脳卒中など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。世界のCVDの罹患率の増加は、不健康な食生活、座りがちなライフスタイル、肥満、高齢化などの危険因子の増加と関連しています。ヘテロ接合型家族性高コレステロール血症の効果的な管理は、動脈硬化や心臓関連の合併症の主要な危険因子である高コレステロール値をコントロールすることによって、心血管疾患を予防する上で重要な役割を果たします。例えば、米国の政府機関である疾病対策予防センター（CDC）によると、米国では2022年に約80万5,000人が心臓発作に見舞われ、そのうち60万5,000人が初発例、20万人が心臓発作の既往歴のある人に発症するといいます。その結果、心血管疾患の有病率の上昇が家族性異型高コレステロール血症管理市場の成長を促進しています。

家族性異型高コレステロール血症管理市場の主要企業は、脂質代謝を改善しコレステロール値を低下させるために、アンジオポエチンに基づく治療法などの革新的な治療法の開発に注力しています。アンジオポエチンは、血管の形成（血管新生）を制御し、血管の安定性を維持するタンパク質ファミリーです。例えば、2023年3月、米国のバイオテクノロジー企業であるリジェネロン・ファーマシューティカルズ社は、ホモ接合性家族性高コレステロール血症（HoFH）の5歳から11歳の小児に対するエブキーザ（evinacumab-dgnb）の承認を米国食品医薬品局（FDA）から取得しました。このファースト・イン・クラスのモノクローナル抗体は、脂質代謝を阻害するタンパク質であるANGPTL3を阻害することにより、低比重リポタンパク質（LDL）コレステロールおよびトリグリセリド値を低下させる。今回の承認は、治療選択肢が限られており、心血管イベントのリスクが高い小児患者に新たな治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界家族性異型高コレステロール血症管理PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の家族性異型高コレステロール血症管理市場：成長率分析
  • 世界の家族性異型高コレステロール血症管理市場の実績：規模と成長, 2019-2024
  • 世界の家族性異型高コレステロール血症管理市場の予測：規模と成長, 2024-2029, 2034F
  • 世界家族性異型高コレステロール血症管理総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の家族性異型高コレステロール血症管理市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • スタチン
  • エゼチミブ
  • PCSK9阻害剤
  • ロミタピド
  • ミポメルセン
  • 世界の家族性異型高コレステロール血症管理市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • オーラル
  • 注射剤
  • 静脈内
  • 世界の家族性異型高コレステロール血症管理市場患者の人口統計別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 子供たち
  • 大人
  • お年寄り
  • 世界の家族性異型高コレステロール血症管理市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 医療センター
  • クリニック
  • その他の用途
  • 世界の家族性異型高コレステロール血症管理市場スタチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • アトルバスタチン
  • シンバスタチン
  • ロスバスタチン
  • プラバスタチン
  • 世界の家族性異型高コレステロール血症管理市場エゼチミブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • エゼチミブ（単剤療法）
  • エゼチミブ併用療法（スタチン併用）
  • 世界の家族性異型高コレステロール血症管理市場PCSK9阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • アリロクマブ
  • エボロクマブ
  • 世界の家族性異型高コレステロール血症管理市場ロミタピドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ロミタピド（単剤療法）
  • ロミタピド併用療法
  • 世界の家族性異型高コレステロール血症管理市場ミポメルセンのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ミポメルセン（単剤療法）
  • ミポメルセン併用療法

第7章 地域別・国別分析

  • 世界の家族性異型高コレステロール血症管理市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の家族性異型高コレステロール血症管理市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 家族性異型高コレステロール血症管理市場：競合情勢
  • 家族性異型高コレステロール血症管理市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Sanofi S.A.
  • Bristol-Myers Squibb
  • AstraZeneca plc
  • Novartis International AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Merck KGaA
  • Regeneron Pharmaceuticals Inc.
  • Ipsen S.A.
  • Chiesi Farmaceutici S.p.A.
  • Ferring Pharmaceuticals Limited
  • Esperion Therapeutics Inc.
  • Aegerion Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 家族性異型高コレステロール血症管理市場2029：新たな機会を提供する国
  • 家族性異型高コレステロール血症管理市場2029：新たな機会を提供するセグメント
  • 家族性異型高コレステロール血症管理市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34070

Heterozygous familial hypercholesterolemia (HeFH) management is a comprehensive strategy aimed at controlling elevated low-density lipoprotein cholesterol (LDL-C) levels in individuals with a genetic predisposition to high cholesterol. The goal is to lower the risk of premature cardiovascular disease (CVD) through lifestyle modifications, lipid-lowering medications, and, in certain cases, advanced treatments such as lipoprotein apheresis.

The primary treatment options for HeFH management include statins, ezetimibe, PCSK9 inhibitors, lomitapide, and mipomersen. Statins are a class of medications that lower cholesterol levels by inhibiting HMG-CoA reductase, a key enzyme in cholesterol production in the liver. The available routes of administration include oral, injectable, and intravenous. The treatment applies to various patient demographics, including children, adults, and the elderly, and is utilized in multiple healthcare settings such as hospitals, medical centers, clinics, and others.

The heterozygous familial hypercholesterolemia management market research report is one of a series of new reports from The Business Research Company that provides heterozygous familial hypercholesterolemia management market statistics, including the heterozygous familial hypercholesterolemia management industry global market size, regional shares, competitors with the heterozygous familial hypercholesterolemia management market share, detailed heterozygous familial hypercholesterolemia management market segments, market trends, and opportunities, and any further data you may need to thrive in the heterozygous familial hypercholesterolemia management industry. This heterozygous familial hypercholesterolemia management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The heterozygous familial hypercholesterolemia management market size has grown rapidly in recent years. It will grow from $10.84 billion in 2024 to $12.07 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth during the historic period can be attributed to the increasing prevalence of cardiovascular diseases, government initiatives, rising investment in research and development activities, greater awareness and diagnosis of HeFH, and the growing demand for personalized therapies.

The heterozygous familial hypercholesterolemia management market size is expected to see rapid growth in the next few years. It will grow to $18.37 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth during the forecast period can be attributed to the expansion of telehealth services, the rising prevalence of chronic illnesses, the increasing number of clinical trials, the growing geriatric population, and the surge in drug pipeline developments. Key trends in the forecast period include the integration of digital health solutions, advancements in therapeutic options, the development of combination therapies, technological innovations, and the emergence of novel treatments.

The increasing prevalence of cardiovascular diseases is expected to drive the expansion of the heterozygous familial hypercholesterolemia management market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The growing incidence of CVDs worldwide is linked to rising risk factors such as unhealthy diets, sedentary lifestyles, obesity, and an aging population. Effective management of heterozygous familial hypercholesterolemia plays a vital role in preventing cardiovascular diseases by controlling high cholesterol levels, a major risk factor for atherosclerosis and heart-related complications. For example, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, approximately 805,000 people in the United States suffered a heart attack in 2022, with 605,000 being first-time cases and 200,000 occurring in individuals with a previous history of heart attacks. As a result, the rising prevalence of cardiovascular diseases is fueling the growth of the heterozygous familial hypercholesterolemia management market.

Leading companies in the heterozygous familial hypercholesterolemia management market are focusing on developing innovative treatments, such as angiopoietin-based therapies, to improve lipid metabolism and lower cholesterol levels. Angiopoietins are a family of proteins that regulate blood vessel formation (angiogenesis) and maintain vascular stability. For instance, in March 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Evkeeza (evinacumab-dgnb) for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). This first-in-class monoclonal antibody works by inhibiting ANGPTL3, a protein that disrupts lipid metabolism, thereby reducing low-density lipoprotein (LDL) cholesterol and triglyceride levels. This approval provides a novel therapeutic option for pediatric patients with limited treatment alternatives and a high risk of cardiovascular events.

In February 2025, Tempus AI Inc., a US-based testing laboratory company, acquired Ambry Genetics for an undisclosed amount. This acquisition aims to enhance diagnostics and patient care by integrating artificial intelligence with genetic testing and expanding into new disease areas. Ambry Genetics Corporation, a US-based company, specializes in genetic testing for heterozygous familial hypercholesterolemia (HeFH).

Major players in the heterozygous familial hypercholesterolemia management market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Ipsen S.A., Chiesi Farmaceutici S.p.A., Ferring Pharmaceuticals Limited, Esperion Therapeutics Inc., Aegerion Pharmaceuticals Inc., Verve Therapeutics Inc.

North America was the largest region in the heterozygous familial hypercholesterolemia management market in 2024. The regions covered in heterozygous familial hypercholesterolemia management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the heterozygous familial hypercholesterolemia management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The heterozygous familial hypercholesterolemia management market includes revenues earned by entities by providing services such as genetic testing and diagnosis, cholesterol monitoring, and lifestyle counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Heterozygous Familial Hypercholesterolemia Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on heterozygous familial hypercholesterolemia management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for heterozygous familial hypercholesterolemia management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The heterozygous familial hypercholesterolemia management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment Type: Statins; Ezetimibe; PCSK9 Inhibitors; Lomitapide; Mipomersen
  • 2) By Route Of Administration: Oral; Injectable; Intravenous
  • 3) By Patient Demographics: Children; Adults; Elderly
  • 4) By Application: Hospitals; Medical Centers; Clinics; Other Applications
  • Subsegments:
  • 1) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin
  • 2) By Ezetimibe: Ezetimibe (Monotherapy); Ezetimibe Combination Therapy (With Statins)
  • 3) By PCSK9 Inhibitors: Alirocumab; Evolocumab
  • 4) By Lomitapide: Lomitapide (Monotherapy); Lomitapide Combination Therapy
  • 5) By Mipomersen: Mipomersen (Monotherapy); Mipomersen Combination Therapy
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Heterozygous Familial Hypercholesterolemia Management Market Characteristics

3. Heterozygous Familial Hypercholesterolemia Management Market Trends And Strategies

4. Heterozygous Familial Hypercholesterolemia Management Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Heterozygous Familial Hypercholesterolemia Management Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Heterozygous Familial Hypercholesterolemia Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Heterozygous Familial Hypercholesterolemia Management Market Growth Rate Analysis
  • 5.4. Global Heterozygous Familial Hypercholesterolemia Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Heterozygous Familial Hypercholesterolemia Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Heterozygous Familial Hypercholesterolemia Management Total Addressable Market (TAM)

6. Heterozygous Familial Hypercholesterolemia Management Market Segmentation

  • 6.1. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Statins
  • Ezetimibe
  • PCSK9 Inhibitors
  • Lomitapide
  • Mipomersen
  • 6.2. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Injectable
  • Intravenous
  • 6.3. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Children
  • Adults
  • Elderly
  • 6.4. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Medical Centers
  • Clinics
  • Other Applications
  • 6.5. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Atorvastatin
  • Simvastatin
  • Rosuvastatin
  • Pravastatin
  • 6.6. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Ezetimibe, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ezetimibe (Monotherapy)
  • Ezetimibe Combination Therapy (With Statins)
  • 6.7. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of PCSK9 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alirocumab
  • Evolocumab
  • 6.8. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Lomitapide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lomitapide (Monotherapy)
  • Lomitapide Combination Therapy
  • 6.9. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Mipomersen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mipomersen (Monotherapy)
  • Mipomersen Combination Therapy

7. Heterozygous Familial Hypercholesterolemia Management Market Regional And Country Analysis

  • 7.1. Global Heterozygous Familial Hypercholesterolemia Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Heterozygous Familial Hypercholesterolemia Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market

  • 8.1. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Heterozygous Familial Hypercholesterolemia Management Market

  • 9.1. China Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 9.2. China Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Heterozygous Familial Hypercholesterolemia Management Market

  • 10.1. India Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Heterozygous Familial Hypercholesterolemia Management Market

  • 11.1. Japan Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 11.2. Japan Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Heterozygous Familial Hypercholesterolemia Management Market

  • 12.1. Australia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Heterozygous Familial Hypercholesterolemia Management Market

  • 13.1. Indonesia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Heterozygous Familial Hypercholesterolemia Management Market

  • 14.1. South Korea Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 14.2. South Korea Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Heterozygous Familial Hypercholesterolemia Management Market

  • 15.1. Western Europe Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 15.2. Western Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Heterozygous Familial Hypercholesterolemia Management Market

  • 16.1. UK Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Heterozygous Familial Hypercholesterolemia Management Market

  • 17.1. Germany Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Heterozygous Familial Hypercholesterolemia Management Market

  • 18.1. France Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Heterozygous Familial Hypercholesterolemia Management Market

  • 19.1. Italy Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Heterozygous Familial Hypercholesterolemia Management Market

  • 20.1. Spain Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market

  • 21.1. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 21.2. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Heterozygous Familial Hypercholesterolemia Management Market

  • 22.1. Russia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Heterozygous Familial Hypercholesterolemia Management Market

  • 23.1. North America Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 23.2. North America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Heterozygous Familial Hypercholesterolemia Management Market

  • 24.1. USA Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 24.2. USA Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Heterozygous Familial Hypercholesterolemia Management Market

  • 25.1. Canada Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 25.2. Canada Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Heterozygous Familial Hypercholesterolemia Management Market

  • 26.1. South America Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 26.2. South America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Heterozygous Familial Hypercholesterolemia Management Market

  • 27.1. Brazil Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Heterozygous Familial Hypercholesterolemia Management Market

  • 28.1. Middle East Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 28.2. Middle East Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Heterozygous Familial Hypercholesterolemia Management Market

  • 29.1. Africa Heterozygous Familial Hypercholesterolemia Management Market Overview
  • 29.2. Africa Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Heterozygous Familial Hypercholesterolemia Management Market Competitive Landscape And Company Profiles

  • 30.1. Heterozygous Familial Hypercholesterolemia Management Market Competitive Landscape
  • 30.2. Heterozygous Familial Hypercholesterolemia Management Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Heterozygous Familial Hypercholesterolemia Management Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Bristol-Myers Squibb
  • 31.3. AstraZeneca plc
  • 31.4. Novartis International AG
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. Eli Lilly and Company
  • 31.7. Gilead Sciences Inc.
  • 31.8. Amgen Inc.
  • 31.9. Merck KGaA
  • 31.10. Regeneron Pharmaceuticals Inc.
  • 31.11. Ipsen S.A.
  • 31.12. Chiesi Farmaceutici S.p.A.
  • 31.13. Ferring Pharmaceuticals Limited
  • 31.14. Esperion Therapeutics Inc.
  • 31.15. Aegerion Pharmaceuticals Inc.

32. Global Heterozygous Familial Hypercholesterolemia Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Heterozygous Familial Hypercholesterolemia Management Market

34. Recent Developments In The Heterozygous Familial Hypercholesterolemia Management Market

35. Heterozygous Familial Hypercholesterolemia Management Market High Potential Countries, Segments and Strategies

  • 35.1 Heterozygous Familial Hypercholesterolemia Management Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Heterozygous Familial Hypercholesterolemia Management Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Heterozygous Familial Hypercholesterolemia Management Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer